Phase II studies of nebulised Arikace in CF patients with<i>Pseudomonas aeruginosa</i>infection

2013219 citationsJournal Articlehybrid Open Access

Authors

Once-daily Arikace demonstrated acute tolerability, safety, biologic activity and efficacy in patients with CF with P aeruginosa infection.

Responsible consumption and production

Published in: Thorax

Volume 68, Issue 9, pp. 818-825

Field-Weighted Citation Impact: 17.53